Skip to main content
Erschienen in: Tumor Biology 4/2016

09.11.2015 | Original Article

RETRACTED ARTICLE: miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma

verfasst von: Shujun Wu, Guojun Zhang, Ping Li, Shanshan Chen, Furui Zhang, Juan Li, Chenyang Jiang, Xiaonan Chen, Yuanyuan Wang, Yuwen Du, Qianqian Sun, Guoqiang Zhao

Erschienen in: Tumor Biology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

MiR-198 is involved in tumorigenesis, migration, invasion, and metastasis of various malignant cancers. However, the exact expression levels of miR-198 and the molecular mechanism underlying its role in lung adenocarcinoma require further exploration. In this study, quantitative real-time PCR was applied to study miR-198 and serine hydroxymethyltransferase 1 (SHMT1) expression in 47 paired lung adenocarcinoma tissues and adjacent nontumor lung tissues. Clinicopathological characters were analyzed. Pearson’s correlation analysis was used to detect the relationship between miR-198 and SHMT1 expression. The function of miR-198 was explored by measuring cell proliferation, cell apoptosis, and the cell-cycle in vitro and in vivo. The target gene of miR-198 was certified using dual luciferase report assay. We found that in lung adenocarcinoma, miR-198 was significantly downregulated and SHMT1 was inversely upregulated. A strong negative correlation was noticed between miR-198 and SHMT1 expression. Further analysis revealed that miR-198 expression was associated with TNM stage and lymph node metastasis. Upregulated miR-198 could inhibit cell proliferation, enhance cell apoptosis, and lead to cell-cycle arrest in lung adenocarcinoma, which showed a more effective alteration than SHMT1 siRNA. Moreover, we identified SHMT1 as a target gene of miR-198. In conclusion, miR-198 suppressed proliferation of lung adenocarcinoma cells both in vitro and in vivo by directly targeting SHMT1. miR-198 may be a potential therapeutic target for lung adenocarcinoma in the near future.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics: 2015. CA Cancer J Clin. 2015;65:5–29.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics: 2015. CA Cancer J Clin. 2015;65:5–29.CrossRef
2.
Zurück zum Zitat Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef
3.
Zurück zum Zitat Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–92.CrossRef Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–92.CrossRef
4.
Zurück zum Zitat Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.CrossRef Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.CrossRef
5.
Zurück zum Zitat Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol. 2014;4:157.CrossRef Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol. 2014;4:157.CrossRef
6.
Zurück zum Zitat Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet. 2014;5:54.CrossRef Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet. 2014;5:54.CrossRef
7.
Zurück zum Zitat Senthil K, Venugopa Joy J, Tae-Hun K, Yong L, Si-Si W, et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol. 2010;298:G101–6.CrossRef Senthil K, Venugopa Joy J, Tae-Hun K, Yong L, Si-Si W, et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol. 2010;298:G101–6.CrossRef
8.
Zurück zum Zitat Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22:165–73.CrossRef Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22:165–73.CrossRef
9.
Zurück zum Zitat Farazi TA, Spitzer JI, Tuschl T. miRNAs in human cancer. J Pathol. 2011;223:102–15.CrossRef Farazi TA, Spitzer JI, Tuschl T. miRNAs in human cancer. J Pathol. 2011;223:102–15.CrossRef
10.
Zurück zum Zitat Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.CrossRef Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.CrossRef
11.
Zurück zum Zitat Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep. 2014;4:6145.CrossRef Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep. 2014;4:6145.CrossRef
12.
Zurück zum Zitat Ye L, Li S, Ye D, Yang D, Yue F, Guo Y, et al. Livin expression may be regulated by miR-198 in human prostate cancer cell lines. Eur J Cancer. 2013;49:734–40.CrossRef Ye L, Li S, Ye D, Yang D, Yue F, Guo Y, et al. Livin expression may be regulated by miR-198 in human prostate cancer cell lines. Eur J Cancer. 2013;49:734–40.CrossRef
13.
Zurück zum Zitat Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.CrossRef Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.CrossRef
14.
Zurück zum Zitat Yang J, Zhao H, Yu X, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 2014;115:987–95.CrossRef Yang J, Zhao H, Yu X, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 2014;115:987–95.CrossRef
15.
Zurück zum Zitat Anderson DD, Woeller CF, Chiang EP, Shane B, Stover PJ. Serine hydroxymethyltransferase anchors de novo thymidylate synthesis pathway to nuclear lamina for DNA synthesis. J Biol Chem. 2012;287:7051–62.CrossRef Anderson DD, Woeller CF, Chiang EP, Shane B, Stover PJ. Serine hydroxymethyltransferase anchors de novo thymidylate synthesis pathway to nuclear lamina for DNA synthesis. J Biol Chem. 2012;287:7051–62.CrossRef
16.
Zurück zum Zitat Paone A, Marani M, Fiascarelli A, Rinaldo S, Giardina G, Contestabile R, et al. SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation. Cell Death Dis. 2014;5, e1525.CrossRef Paone A, Marani M, Fiascarelli A, Rinaldo S, Giardina G, Contestabile R, et al. SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation. Cell Death Dis. 2014;5, e1525.CrossRef
17.
Zurück zum Zitat Xing RC, Zheng J, Zheng WH, Qin ZP, Liu W, Yao RC. Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance. Genet Mol Res. 2015;14:5785–92.CrossRef Xing RC, Zheng J, Zheng WH, Qin ZP, Liu W, Yao RC. Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance. Genet Mol Res. 2015;14:5785–92.CrossRef
18.
Zurück zum Zitat Maemondo M, Inoue A, Kobayashi K. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med. 2010;362:2380–88.CrossRef Maemondo M, Inoue A, Kobayashi K. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med. 2010;362:2380–88.CrossRef
19.
Zurück zum Zitat Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer. 2015;121:E1–6.CrossRef Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer. 2015;121:E1–6.CrossRef
20.
Zurück zum Zitat Chen Z, Liu X, Zhao J, Yang H, Teng X. Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin Exp Pathol. 2014;7:8039–45.PubMedPubMedCentral Chen Z, Liu X, Zhao J, Yang H, Teng X. Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin Exp Pathol. 2014;7:8039–45.PubMedPubMedCentral
21.
Zurück zum Zitat Takeuchi S, Yano S. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance. Respir Investig. 2014;52:348–56.CrossRef Takeuchi S, Yano S. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance. Respir Investig. 2014;52:348–56.CrossRef
22.
Zurück zum Zitat Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr Oncol. 2015;22:e183–215.CrossRef Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr Oncol. 2015;22:e183–215.CrossRef
23.
Zurück zum Zitat Paiardini A, Fiascarelli A, Rinaldo S, Daidone F, Giardina G, Koes DR, et al. Screening and in vitro testing of antifolate inhibitors of human cytosolic serine hydroxymethyltransferase. ChemMedChem. 2015;10:490–7.CrossRef Paiardini A, Fiascarelli A, Rinaldo S, Daidone F, Giardina G, Koes DR, et al. Screening and in vitro testing of antifolate inhibitors of human cytosolic serine hydroxymethyltransferase. ChemMedChem. 2015;10:490–7.CrossRef
24.
Zurück zum Zitat Kim HM, Jung WH, Koo JS. Site-specific metabolic phenotypes in metastatic breast cancer. J Transl Med. 2014;12:354.CrossRef Kim HM, Jung WH, Koo JS. Site-specific metabolic phenotypes in metastatic breast cancer. J Transl Med. 2014;12:354.CrossRef
25.
Zurück zum Zitat Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012;148:259–72.CrossRef Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012;148:259–72.CrossRef
26.
Zurück zum Zitat Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, et al. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol. 2015;10:38.CrossRef Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, et al. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol. 2015;10:38.CrossRef
27.
Zurück zum Zitat Andrea V, Tyler J. miRNAs and cancer: a little RNA goes a long way. Cell. 2009;136:586–91.CrossRef Andrea V, Tyler J. miRNAs and cancer: a little RNA goes a long way. Cell. 2009;136:586–91.CrossRef
28.
Zurück zum Zitat Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18:215–22.CrossRef Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18:215–22.CrossRef
Metadaten
Titel
RETRACTED ARTICLE: miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma
verfasst von
Shujun Wu
Guojun Zhang
Ping Li
Shanshan Chen
Furui Zhang
Juan Li
Chenyang Jiang
Xiaonan Chen
Yuanyuan Wang
Yuwen Du
Qianqian Sun
Guoqiang Zhao
Publikationsdatum
09.11.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4369-z

Weitere Artikel der Ausgabe 4/2016

Tumor Biology 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.